Suppr超能文献

抗革兰氏阳性菌和革兰氏阴性菌抗菌肽的来源:我们的研究经验。

The sources of antimicrobial peptides against Gram-positives and Gramnegatives: our research experience.

作者信息

Rizzetto Giulio, Gambini Daisy, Maurizi Andrea, Molinelli Elisa, De Simoni Edoardo, Pallotta Francesco, Brescini Lucia, Cirioni Oscar, Offidani Annamaria, Simonetti Oriana, Giacometti Andrea

机构信息

Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.

Clinic of Infectious Diseases, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.

出版信息

Infez Med. 2023 Sep 1;31(3):306-322. doi: 10.53854/liim-3103-5. eCollection 2023.

Abstract

Antibiotic resistance of Gram-positive and Gramnegative bacteria is becoming increasingly prevalent. For this reason, the search for new molecules that can overcome current resistance and also recover antibiotics that are no longer effective is becoming increasingly urgent. Our research group at the 'Polytechnic University of Marche' managed to study the effectiveness of certain antimicrobial peptides (AMPs). We decided to review our experience with AMPs by classifying them according to their origin and evaluating their effect on Gram-negative and Gram-positive bacteria. AMPs can derive from mammals, amphibians, microorganisms, and insects. In conclusion, our research experience shows that the richest source of AMPs are amphibians. However, the studies done are mainly in vitro or in animal models, requiring further human studies to assess the efficacy and safety of these molecules. AMPs may be a new therapeutic option for infections sustained by multi-resistant micro-organisms and for overcoming the mechanisms of resistance to antibiotics currently used. In particular, combining AMPs with antibiotics, including those with limited antimicrobial activity due to antimicrobial resistance, has often shown a synergistic effect, increasing or restoring their efficacy. The possibility of using manageable and relatively safe antibiotics again is crucial, considering the widespread increase in bacterial resistance in hospitals and the community. Despite a plethora of research on AMPs and their application as potential treatment on infectious diseases, this area needs further exploration. There is evidence that the characteristics of AMPs can seriously improve through structural chemical modifications and different delivery systems to become alternatives drugs to conventional antibiotics. The aim is to provide an overview of the possible sources from which AMPs are extracted, evaluating their action exclusively on Gram-positive and negative bacteria. This is to determine, based on our experience, which might be the most promising sources of AMPs for future research as well.

摘要

革兰氏阳性菌和革兰氏阴性菌的抗生素耐药性正变得越来越普遍。因此,寻找能够克服当前耐药性并恢复不再有效的抗生素的新分子变得越来越紧迫。我们马尔凯理工大学的研究小组成功研究了某些抗菌肽(AMPs)的有效性。我们决定通过根据抗菌肽的来源对其进行分类并评估它们对革兰氏阴性菌和革兰氏阳性菌的作用来回顾我们对抗菌肽的经验。抗菌肽可以来源于哺乳动物、两栖动物、微生物和昆虫。总之,我们的研究经验表明,抗菌肽最丰富的来源是两栖动物。然而,所做的研究主要是在体外或动物模型中进行的,需要进一步的人体研究来评估这些分子的疗效和安全性。抗菌肽可能是治疗多重耐药微生物感染和克服目前使用的抗生素耐药机制的一种新的治疗选择。特别是,将抗菌肽与抗生素联合使用,包括那些由于抗菌耐药性而抗菌活性有限的抗生素,常常显示出协同效应,增强或恢复它们的疗效。考虑到医院和社区中细菌耐药性的广泛增加,再次使用易于管理且相对安全的抗生素的可能性至关重要。尽管对抗菌肽及其作为传染病潜在治疗方法的应用进行了大量研究,但这一领域仍需进一步探索。有证据表明,通过结构化学修饰和不同的递送系统,抗菌肽的特性可以得到显著改善,从而成为传统抗生素的替代药物。目的是概述提取抗菌肽的可能来源,仅评估它们对革兰氏阳性菌和阴性菌的作用。这也是根据我们的经验来确定哪些可能是未来研究中最有前景的抗菌肽来源。

相似文献

1
The sources of antimicrobial peptides against Gram-positives and Gramnegatives: our research experience.
Infez Med. 2023 Sep 1;31(3):306-322. doi: 10.53854/liim-3103-5. eCollection 2023.
2
Our Experience over 20 Years: Antimicrobial Peptides against Gram Positives, Gram Negatives, and Fungi.
Pharmaceutics. 2022 Dec 22;15(1):40. doi: 10.3390/pharmaceutics15010040.
3
Designed Antimicrobial Peptides Against Gram-Negative Bacteria.
Front Microbiol. 2021 Nov 16;12:715246. doi: 10.3389/fmicb.2021.715246. eCollection 2021.
5
Functional synergy of α-helical antimicrobial peptides and traditional antibiotics against Gram-negative and Gram-positive bacteria in vitro and in vivo.
Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):197-204. doi: 10.1007/s10096-014-2219-3. Epub 2014 Aug 30.
6
Evaluation of Antimicrobial Peptides from the Black Soldier Fly () against a Selection of Human Pathogens.
Microbiol Spectr. 2022 Feb 23;10(1):e0166421. doi: 10.1128/spectrum.01664-21. Epub 2022 Jan 5.
7
How to Combat Gram-Negative Bacteria Using Antimicrobial Peptides: A Challenge or an Unattainable Goal?
Antibiotics (Basel). 2021 Dec 7;10(12):1499. doi: 10.3390/antibiotics10121499.
8
The Silkworm as a Source of Natural Antimicrobial Preparations: Efficacy on Various Bacterial Strains.
Antibiotics (Basel). 2021 Nov 2;10(11):1339. doi: 10.3390/antibiotics10111339.
9
Advancements in peptide-based antimicrobials: A possible option for emerging drug-resistant infections.
Adv Colloid Interface Sci. 2024 Nov;333:103282. doi: 10.1016/j.cis.2024.103282. Epub 2024 Sep 6.
10
Antimicrobial peptides as potential anti-biofilm agents against multidrug-resistant bacteria.
J Microbiol Immunol Infect. 2017 Aug;50(4):405-410. doi: 10.1016/j.jmii.2016.12.005. Epub 2017 Jun 26.

引用本文的文献

1
Snake Venom Compounds: A New Frontier in the Battle Against Antibiotic-Resistant Infections.
Toxins (Basel). 2025 May 1;17(5):221. doi: 10.3390/toxins17050221.
2
Frog Skin Peptides Hylin-a1, AR-23, and RV-23: Promising Tools Against Carbapenem-Resistant and Infections.
Antibiotics (Basel). 2025 Apr 3;14(4):374. doi: 10.3390/antibiotics14040374.

本文引用的文献

1
Our Experience over 20 Years: Antimicrobial Peptides against Gram Positives, Gram Negatives, and Fungi.
Pharmaceutics. 2022 Dec 22;15(1):40. doi: 10.3390/pharmaceutics15010040.
2
In Vitro Activity of Novel Lipopeptides against Triazole-Resistant .
J Fungi (Basel). 2022 Aug 18;8(8):872. doi: 10.3390/jof8080872.
3
Role of Daptomycin in Cutaneous Wound Healing: A Narrative Review.
Antibiotics (Basel). 2022 Jul 14;11(7):944. doi: 10.3390/antibiotics11070944.
5
Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model.
Antibiotics (Basel). 2021 Oct 5;10(10):1210. doi: 10.3390/antibiotics10101210.
6
Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.
Ther Clin Risk Manag. 2021 Mar 22;17:223-232. doi: 10.2147/TCRM.S271445. eCollection 2021.
8
Synergistic effect of antimicrobial peptide LL-37 and colistin combination against multidrug-resistant isolates.
Future Microbiol. 2021 Mar;16:221-227. doi: 10.2217/fmb-2020-0204. Epub 2021 Mar 1.
10
Antimicrobial peptides: Application informed by evolution.
Science. 2020 May 1;368(6490). doi: 10.1126/science.aau5480.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验